You are here
- Home
Total number of clinical trials
-
collapse
A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Bioequivalence Study Comparing a Pellets Based Sachet Formulation of D961H 20 mg and a Commercial HPMC Capsule of D961H 20 mg After Repeated Oral Administration in Japanese Healthy Male Subjects.
-
collapse
An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain
-
collapse
Open-Label Positron Emission Tomography Study with the Selective β Amyloid Radioligand [18F]AZD4694 to Assess the Effects of Varying Radioligand Mass on Binding Parameters in Healthy Volunteers and Patients with Alzheimer’s Disease
-
collapse
A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status (SAGE)
-
collapse
Prospective study to evaluate the impact of an educational programme about diabetes, comparing to normal clinical practice, on treatment compliance and disease control of people with type 2 diabetes followed in the primary care units in Portugal
-
collapse
A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of AZD8931 In Combination with Anastrozole in Post menopausal Women With Hormone Receptor positive, Endocrine Therapy naive, Locally advanced or Metastatic Breast Cancer (MINT)
-
collapse
A Phase I, Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ceftaroline after Different Intravenous Dose Regimens of Ceftaroline Fosamil to Healthy Subjects
-
collapse
A Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN® treatment under condition of actual usage in clinical practice
-
collapse
A long term open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or combination therapies with anti-diabetic drugs in Japanese subjects with type 2 diabetes who have inadequate glycemic control
-
collapse
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea
